ES2506090T3 - Inhibidores de la (ADP-ribosa) polimerasa - Google Patents
Inhibidores de la (ADP-ribosa) polimerasa Download PDFInfo
- Publication number
- ES2506090T3 ES2506090T3 ES07855102.5T ES07855102T ES2506090T3 ES 2506090 T3 ES2506090 T3 ES 2506090T3 ES 07855102 T ES07855102 T ES 07855102T ES 2506090 T3 ES2506090 T3 ES 2506090T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- independently
- unsubstituted
- nhc
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
Abstract
Un compuesto que tiene la fórmula III o una sal del mismo, donde A1 y A2, junto con los átomos a los que están unidos son pirrol, imidazol, piperidina o pirrolidina; uno de R1A y R1B es H, y el otro es R1, C(O)R1, C(O)NHR1 o C(O)N(R1)2; R1 es R2, R3, R4 o R5; R2 es fenilo; R3 es heteroareno; R4 es cicloalquilo o heterocicloalquilo; R5 es alquilo que está sin sustituir o sustituido con uno o dos de R6, NHR6, N(R6)2, C(O)R6, NR6C(O)R6 o NR6S(O)2R6 independientemente seleccionados; R6 es R7, R8, R9 o R10; R7 es fenilo; R8 es heteroareno; R9 es cicloalquilo o heterocicloalquilo; R10 es alquilo que está sin sustituir o sustituido con uno o dos de R11, C(O)OH, N(R11)2, C(O)R11 o C(O)OR11 independientemente seleccionados; R11 es R12, R14 o R14A; R12 es fenilo; R14 es cicloalquilo o heterocicloalquilo; R14A es alquilo; R15 es R18 o R19; R18 es heterocicloalquilo; R19 es alquilo; donde los restos representados por R18 están independientemente sin sustituir o independientemente sustituidos con R23; R23 es R27; R27 es alquilo, cada uno de los cuales está sustituido con R28; R28 es fenilo; donde los restos representados por R2, R4 y R9 están independientemente sin sustituir o independientemente sustituidos con R15, SO2R15, NH2, N(R15)2 o (O); y donde los restos representados por R3, R7, R8, R12 y R14 están independientemente sin sustituir o adicionalmente sin sustituir o independientemente sustituidos o adicionalmente sustituidos con R15, OR15, SR15, S(O)R15, SO2R15, NH2, NHR15, N(R15)2, C(O)R15, C(O)NH2, C(O)NHR15, C(O)N(R15)2, NHC(O)R15, NR15C(O)R15, NHSO2R15, NR15SO2R15, NHC(O)OR15, NR15C(O)OR15, SO2NH2, SO2NHR15, SO2N(R15)2, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)N(R15)2, OH, (O), C(O)OH, CN, CF3, OCF3, CF2CF3, F, Cl, Br o I.
Description
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88227006P | 2006-12-28 | 2006-12-28 | |
US882270P | 2006-12-28 | ||
PCT/US2007/087250 WO2008082887A2 (en) | 2006-12-28 | 2007-12-12 | Inhibitors of poly(adp-ribose)polymerase |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2506090T3 true ES2506090T3 (es) | 2014-10-13 |
Family
ID=39154384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES07855102.5T Active ES2506090T3 (es) | 2006-12-28 | 2007-12-12 | Inhibidores de la (ADP-ribosa) polimerasa |
Country Status (8)
Country | Link |
---|---|
US (1) | US7790721B2 (es) |
EP (1) | EP2114948B1 (es) |
JP (3) | JP5496680B2 (es) |
CN (1) | CN101616919B (es) |
CA (1) | CA2672860C (es) |
ES (1) | ES2506090T3 (es) |
MX (1) | MX2009007053A (es) |
WO (1) | WO2008082887A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007138355A1 (en) * | 2006-05-31 | 2007-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
EP2502628B1 (en) | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
CA2740900C (en) | 2008-11-03 | 2019-09-24 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
BRPI0922224A2 (pt) | 2008-12-08 | 2016-08-02 | Vm Pharma Llc | composições de inibidores de proteína tirosina quiinase receptora. |
RU2014147175A (ru) * | 2009-05-22 | 2015-06-27 | Эббви Инк. | Модуляторы рецепторов 5-нт и способы их применения |
EP2459561A1 (en) * | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
RU2015140748A (ru) * | 2010-05-21 | 2018-12-26 | Эббви Инк. | Модуляторы 5-нт рецепторов и способы их применения |
EP2691421B1 (en) | 2011-03-31 | 2016-11-09 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
CA2841897A1 (en) * | 2011-07-13 | 2013-01-17 | Santen Pharmaceutical Co., Ltd. | Novel compound having parp inhibitory activity |
EP2802351B1 (en) | 2012-01-09 | 2019-03-27 | ADC Therapeutics SA | Agents for treating triple negative breast cancer |
PE20142186A1 (es) * | 2012-03-28 | 2014-12-29 | Merck Patent Gmbh | Derivados biciclicos de pirazinona |
KR20150011838A (ko) * | 2012-06-20 | 2015-02-02 | 에프. 호프만-라 로슈 아게 | 탄키라아제 억제제로서의 피롤로피라존 |
US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
EP3193874A4 (en) | 2014-09-17 | 2018-04-25 | Mundipharma International Corporation Limited | Crystalline forms of tyrosine kinase inhibitors and their salts |
BR112018009550A2 (pt) | 2015-11-13 | 2018-11-06 | Mavalon Therapeutics Ltd | derivados de 1,4-benzodiazepinona tricíclica substituída como moduladores alostéricos de receptores de glutamato metabotrópico de grupo ii |
CA3049251A1 (en) * | 2017-01-09 | 2018-07-12 | Shuttle Pharmaceuticals, Inc. | Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation |
EP3621620A1 (en) | 2017-05-12 | 2020-03-18 | Mavalon Therapeutics Limited | Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4446323A (en) * | 1983-05-23 | 1984-05-01 | American Home Products Corporation | Tetra- and hexa-hydropyrrolo(1,2-a)quinoxaline and azaquinoxaline derivatives |
DE4228095A1 (de) * | 1992-08-24 | 1994-03-03 | Asta Medica Ag | Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung |
WO1995021842A1 (en) * | 1994-02-11 | 1995-08-17 | Novo Nordisk A/S | Heterocyclic compounds and their preparation and use |
US6635626B1 (en) * | 1997-08-25 | 2003-10-21 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US7026311B2 (en) * | 2002-01-10 | 2006-04-11 | Abbott Gmbh & Co., Kg | Dibenzodiazepine derivatives, their preparation and use |
AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
AU2003284632A1 (en) * | 2002-11-22 | 2004-06-18 | Mitsubishi Pharma Corporation | Isoquinoline compounds and medicinal use thereof |
US20040180898A1 (en) * | 2003-03-03 | 2004-09-16 | Bang-Chi Chen | Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines |
JP2005008604A (ja) | 2003-06-23 | 2005-01-13 | Ono Pharmaceut Co Ltd | ピリダジノン誘導体およびその中間体の製造方法 |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
EP1768674A1 (en) * | 2004-07-16 | 2007-04-04 | ProteoSys AG | Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents |
AU2006204522A1 (en) * | 2005-01-03 | 2006-07-13 | Universita Degli Studi Di Siena | Aryl piperazine derivatives for the treatment of neuropsychiatric disorders |
WO2006094210A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Tetrahydroquinoxalinone sirtuin modulators |
EP1798233A1 (en) | 2005-12-19 | 2007-06-20 | Faust Pharmaceuticals | Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof |
WO2007138355A1 (en) * | 2006-05-31 | 2007-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
GB0615809D0 (en) * | 2006-08-09 | 2006-09-20 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
FR2921927B1 (fr) * | 2007-10-03 | 2012-10-12 | Univ De Montpellier 1 | Imidazo°1,2-a!quinoxalines et derives pour le traitement des cancers |
-
2007
- 2007-12-12 MX MX2009007053A patent/MX2009007053A/es active IP Right Grant
- 2007-12-12 CN CN2007800518625A patent/CN101616919B/zh not_active Expired - Fee Related
- 2007-12-12 CA CA2672860A patent/CA2672860C/en not_active Expired - Fee Related
- 2007-12-12 EP EP07855102.5A patent/EP2114948B1/en active Active
- 2007-12-12 ES ES07855102.5T patent/ES2506090T3/es active Active
- 2007-12-12 WO PCT/US2007/087250 patent/WO2008082887A2/en active Application Filing
- 2007-12-12 JP JP2009544160A patent/JP5496680B2/ja not_active Expired - Fee Related
- 2007-12-27 US US11/964,788 patent/US7790721B2/en not_active Expired - Fee Related
-
2014
- 2014-03-04 JP JP2014041488A patent/JP2014129398A/ja active Pending
-
2016
- 2016-04-07 JP JP2016077054A patent/JP2016164175A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
WO2008082887A2 (en) | 2008-07-10 |
JP5496680B2 (ja) | 2014-05-21 |
US20080161292A1 (en) | 2008-07-03 |
EP2114948A2 (en) | 2009-11-11 |
JP2016164175A (ja) | 2016-09-08 |
CA2672860A1 (en) | 2008-07-10 |
MX2009007053A (es) | 2009-07-09 |
EP2114948B1 (en) | 2014-06-25 |
CN101616919A (zh) | 2009-12-30 |
JP2014129398A (ja) | 2014-07-10 |
CA2672860C (en) | 2013-01-29 |
JP2010514780A (ja) | 2010-05-06 |
US7790721B2 (en) | 2010-09-07 |
CN101616919B (zh) | 2012-10-10 |
WO2008082887A3 (en) | 2008-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2506090T3 (es) | Inhibidores de la (ADP-ribosa) polimerasa | |
AR059620A1 (es) | Moduladores pirrolo - piridinicos de quinasas | |
HRP20100283T8 (en) | Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity | |
PE20081530A1 (es) | Nuevos compuestos 617 | |
AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
ECSP088479A (es) | Derivados de oxadiazol | |
PE20080830A1 (es) | Compuestos derivados de sulfonilo que modulan el receptor cb2 | |
PE20050354A1 (es) | Aminas ciclicas de bace-1 que poseen un sustituyente heterociclico | |
AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
AR055177A1 (es) | Compuestos heterociclicos fusionados utiles como moduladores de cinasa | |
ES2536918T3 (es) | Compuestos de benzoilpirazol y herbicidas que los contienen | |
AR055053A1 (es) | Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas. | |
PE20001063A1 (es) | Nuevos agentes antibacterianos de isoxazolinona | |
CO6210739A2 (es) | Composicion pesticida que comprende un compuesto antralinamida, o su sal y otro pesticida | |
AR090868A1 (es) | Composiciones plaguicidas y procesos relacionados con ellas | |
PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
NO20072690L (no) | Benzenforbindelser med 2 eller flere substituenter | |
AR039933A1 (es) | Indoles sustituidos para tratamiento de desordenes respiratorios | |
UY27317A1 (es) | Resolución de sal quiral | |
AR053342A1 (es) | Quinolonas y naftiridonas 7- maino alquilildenil- heterociclicas | |
AR004002A1 (es) | Composicion util especialmente para el tratamiento y la proteccion de los animales domesticos infestados o susceptibles de ser infestados por parasitos | |
CO5601027A2 (es) | Derivados de imidazol-4-il-etinil-piridina | |
PE20090549A1 (es) | Derivados de imidazolidinona con actividad sobre lxr-alfa y lxr-beta | |
ES2531149T3 (es) | Derivados de 2-piridiniletilcarboxamida y su uso como fungicidas | |
AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b |